用于前列腺癌腔内放射治疗的双靶点结合配体及其药代动力学调控
本研究合成六种对前列腺特异性膜抗原(PSMA)和人血清白蛋白(HSA)亲和力不同的尿素基配体,用131I标记后在LNCaP细胞和临床前前列腺癌模型中评估,并与MIP-1095比较。其中131I-RPS-027表现出良好的肿瘤摄取和滞留,肾脏摄取较MIP-1095降低5倍以上,肿瘤与肾脏比值在注射后24小时大于3:1、72小时增至7:1。
要点
- 131I-RPS-027对PSMA的50%抑制浓度为15 nM,对HSA的解离常数为11.2 μM。
- 131I-RPS-027在注射后48小时内从血液清除,肿瘤摄取为每克10%注射剂量。
- 131I-RPS-027的肾脏摄取较MIP-1095降低5倍以上,肿瘤与肾脏比值24小时大于3:1、72小时为7:1。
核心结论
- RPS-027对PSMA和白蛋白具有双靶向结合能力,在前列腺癌临床前模型中表现出高肿瘤摄取、有利的组织分布和有前景的治疗特性。
- 与现有靶向治疗前列腺癌的配体相比,RPS-027的肿瘤与组织比值预测治疗期间副作用可显著减少。
- 作者以碘/放射性碘作为放射性卤素211At的替代物,提出将RPS-027等双靶点结合配体作为使用211At进行靶向α治疗的下一代放射性药物。
研究设计与样本
- 研究合成六种对PSMA和HSA亲和力不同的新型尿素基配体,用131I标记,在LNCaP细胞中进行体外结合和摄取实验。
- 四种化合物进入前列腺癌临床前模型进一步评估,并与目前处于临床评估阶段的PSMA配体MIP-1095进行比较。
主要发现
- 化合物对PSMA的亲和力在4-40 nM范围,对HSA的亲和力在1-53 μM范围。
- 对HSA亲和力较高(≤2 μM)的化合物表现出高且持续的血池活性以及肾脏摄取降低。
- 131I-RPS-027对PSMA的50%抑制浓度为15 nM,对HSA的解离常数为11.2 μM,在48小时内从血液清除。
- 131I-RPS-027的肿瘤摄取为每克10%注射剂量,并具有良好的滞留。
- 131I-RPS-027的肾脏摄取较MIP-1095降低5倍以上,肿瘤与肾脏比值在注射后24小时大于3:1,72小时增至7:1。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted radiotherapy of prostate cancer (PCa) has emerged recently as a promising approach to the treatment of disseminated disease. A small number of ligands have been evaluated in patients, and although early tumor response is encouraging, relapse rate is high and these compounds localize to the parotid, salivary, and lacrimal glands as well as to the kidney, leading to dose-limiting toxicities and adverse events affecting quality of life. We envision that dual-target binding ligands displaying high affinity for PSMA and appropriate affinity for human serum albumin (HSA) may demonstrate a higher therapeutic index and be suitable for treatment of PCa by targeted α-therapy. Methods: Six novel urea-based ligands with varying affinities for PSMA and HSA were synthesized, labeled with 131I, and evaluated by in vitro binding and uptake assays in LNCaP cells. Four compounds were advanced for further evaluation in a preclinical model of PCa. The compounds were compared with MIP-1095, a PSMA ligand currently in clinical evaluation. Results: The compounds demonstrated affinity for PSMA on the order of 4-40 nM and affinity for HSA in the range of 1-53 μM. Compounds with relatively high affinity for HSA (≤2 μM) showed high and sustained blood-pool activity and reduced uptake in the kidneys. 131I-RPS-027, with a 50% inhibitory concentration (PSMA) of 15 nM and a dissociation constant (HSA) of 11.2 μM, cleared from the blood over the course of 48 h and showed good tumor uptake (10 percentage injected dose per gram) and retention and a greater than 5-fold decrease in kidney uptake relative to MIP-1095. The tumor-to-kidney ratio of 131I-RPS-027 was greater than 3:1 at 24 h after injection, increasing to 7:1 by 72 h. Conclusion: RPS-027 shows dual targeting to PSMA and albumin, resulting in a high tumor uptake, highly favorable tissue distribution, and promising therapeutic profile in a preclinical model of prostate cancer. In comparison to existing ligands proposed for targeted therapy of prostate cancer, RPS-027 has tumor-to-tissue ratios that predict a significant reduction in side effects during therapy. Using iodine/radioiodine as a surrogate for the radiohalogen 211At, we therefore propose dual-target binding ligands such as RPS-027 as next-generation radiopharmaceuticals for targeted α-therapy using 211At.
引用
- Kelly JM, Amor-Coarasa A, Nikolopoulou A, et al. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2017. PMID: 28450562. doi:10.2967/jnumed.116.188722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。